UTv Videos

Timothy Daskivich, MD, MSHPM, noted that guidelines are central to shaping physician behavior and strongly influence clinical practice

Veda Giri, MD, outlines points of consensus and areas of disagreement across national and international guideline recommendations for germline testing in prostate cancer.

Several experts share their thoughts on the impact of the gemcitabine intravesical system for BCG-unresponsive NMIBC.

Ensuring consistent diagnostic quality remains critical.

Stephen J. Freedland, MD, placed dietary guidance within the broader context of survivorship care.

Sia Daneshmand, MD, discusses evolving care strategies after enfortumab vedotin plus pembrolizumab in bladder cancer.

A Lenore Ackerman, MD, discusses a recent guideline amendment that places a greater value on a negative urinalysis in ruling out UTI.

Margaret A. Knoedler, MD, discusses her experience using the Reverse Deflection CVAC System.

Fosnight emphasizes that the cycle of shame, secrecy, and loneliness compounds the burden of urinary incontinence far beyond its physical effects.

John P. Sfakianos, MD, discusses the significance of urine-based biomarkers for intermediate-risk patients and outlines key findings from the STRATA study.

A. Lenore Ackerman, MD, PhD, discusses the renewed emphasis on symptom resolution over microbial eradication in the new AUA guideline for recurrent uUTI in women.

Manuj Agarwal, MD, discusses which patients may be best suited for prostate brachytherapy.

Among men without prostate cancer at baseline, healthier dietary patterns appeared somewhat protective.

Apolo emphasized the value of having robust monotherapy data before advancing into combination strategies.

William C. Huang, MD, discusses data on mitomycin for intravesical solution from the pivotal ENVISION trial and the OPTIMA II study.

Both experts agreed that although the details shift by condition, the core structure of patient-centered decision-making remains constant.

Kevin Koo, MD, MPH, discusses the implications of a digital stone measurement tool for clinical care.

Miles-Thomas emphasized the importance of Northwestern’s thoughtful implementation strategy.

William C. Huang, MD, highlights data from a long-term extension study of the OPTIMA II trial.

Kurtzman stressed that it is difficult to disentangle whether the increased hypertension risk is primarily due to the intervention itself or to the patients’ initial clinical state.

Surprisingly, the Mediterranean diet—which has shown benefits in other areas of health—was not consistently linked to prostate cancer risk reduction.

Kevin Koo, MD, MPH, discusses a recent study on the utility of a digital stone measurement tool for ureteroscopy.

Rana R. McKay, MD, FASCO, outlines findings from a study looking at the somatic, germline, and immunologic landscapes of UTUC and UCB tumors.

35% of patients with renal trauma developed new-onset hypertension, compared with 21% of controls.

Hong Truong, MD, MS, highlights key findings on genetic counseling rates in patients with kidney cancer.

Both experts stress that the framework is not intended to overhaul physicians’ communication styles but rather to highlight overlooked areas.

Experts discuss the ways in which AI could transform patient care and improve physician workflows, particularly for benign prostatic hyperplasia.

Both urologists emphasized that Northwestern’s integrated structure and commitment to innovation allow any urologist within the network to contribute ideas and see them developed into practice.